To better address this issue, we analyzed the effects of PDE7 inhibitor in combination with PTX in 2 cell lines with different cisplatin sensitivities: A2780 (Beaufort et al., 2014), a cisplatin-sensitive cell line isolated from an untreated patient, and OVCAR3 (Hamilton et al., 1983), a cell line established from the malignant ascites of a patient with progressive ovarian adenocarcinoma following combination chemotherapy with cyclophosphamide, adriamycin, and cisplatin. The gene discussed is PDE7A; the disease is ovarian adenocarcinoma.